Quarterly ResultMay 12, 2026, 09:07 AM
Connect Biopharma Q1 Net Loss $19.4M; Cash $46.0M; Clinical Trials Progress
AI Summary
Connect Biopharma reported a net loss of $19.4 million for the first quarter of 2026, with cash and cash equivalents totaling $46.0 million as of March 31, 2026. The company successfully closed a $20.2 million private placement financing, extending its cash runway into the second half of 2027. Business updates highlighted the ongoing Phase 2 Seabreeze STAT studies for asthma and COPD, with topline data anticipated mid-2026, and positive Phase 1 data for IV rademikibart demonstrating rapid lung function improvement.
Key Highlights
- Completed $20.2M private placement financing on March 31, 2026.
- Cash and cash equivalents were $46.0M as of March 31, 2026.
- Net loss for Q1 2026 was $19.4M, or ($0.34) per share.
- Research and development expense increased to $15.0M in Q1 2026 from $6.6M in Q1 2025.
- License and collaboration revenues were $0.2M in Q1 2026, up from $0 in Q1 2025.
- Phase 2 Seabreeze STAT studies for asthma and COPD continue, with topline data expected mid-2026.
- Positive Phase 1 IV rademikibart data showed rapid lung function improvement.
- Cash runway extended into the second half of 2027.
Price Impact
More from CNTB